Pcn248 - Use of Cancer Drugs in the End-Of-Life in Men Dying of Castration-Resistant Prostate Cancer: Population-Based Study

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.330
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Spirituality and End-Of-Life Care in Disadvantaged Men Dying of Prostate Cancer

World Journal of Urology
Urology
2010English

The Contemporary Use of Radium-223 in Metastatic Castration Resistant Prostate Cancer

Clinical Genitourinary Cancer
OncologyUrology
2018English

Guideline Adherence in Docetaxel Treatment of Castration Resistant Prostate Cancer (CRPC) Patients in a Real-World Population: The Castration Resistant Prostate Cancer Registry (CAPRI) in the Netherlands

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

Targeting Cancer Stem Cells in Castration-Resistant Prostate Cancer

Clinical Cancer Research
Cancer ResearchOncology
2015English

A Phase I Study of Niclosamide in Combination With Enzalutamide in Men With Castration-Resistant Prostate Cancer

PLoS ONE
Multidisciplinary
2018English

Visceral Disease in Castration-Resistant Prostate Cancer

European Urology
Urology
2014English

Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer

Yearbook of Paediatric Endocrinology
2019English

Aggressive Variants of Castration-Resistant Prostate Cancer

Clinical Cancer Research
Cancer ResearchOncology
2014English

Mechanisms of Acquired Resistance to Androgen Receptor Targeting Drugs in Castration-Resistant Prostate Cancer

Expert Review of Anticancer Therapy
OncologyPharmacology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy